Immunoadsorption for systemic lupus erythematosus.

Area of Science:

• Rheumatology
• Nephrology
• Immunology

Background:

• Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease requiring effective treatments for severe cases.
• Conventional therapies may be insufficient for refractory SLE patients.
• Emerging biologicals offer alternative treatments but lack robust clinical trial data in SLE.

Observation:

• Immunoadsorption (IAS) is utilized as a rescue therapy for severe SLE, targeting pathogenic immunocomplexes and autoantibodies.
• Long-term observational data suggest IAS efficacy and a favorable safety profile regarding infection risk compared to other extracorporeal procedures.
• Randomized controlled trials (RCTs) for IAS in SLE are notably absent.
• Biological therapies for severe SLE, while easier to administer, also lack demonstrated benefit from RCTs.

Findings:

• IAS effectively removes immune complexes and autoantibodies in severe SLE patients.
• Observational studies indicate IAS is a safe and effective rescue therapy, particularly when conventional treatments are ineffective or contraindicated.
• The absence of RCTs for IAS and recent biologicals highlights a gap in evidence-based treatment validation for severe SLE.

Implications:

• IAS remains a valuable therapeutic option for severe, refractory SLE, especially in specific clinical scenarios like pregnancy.
• Further high-quality clinical trials are needed to definitively establish the efficacy of both IAS and newer biologicals in SLE management.
• The review emphasizes the continued relevance of IAS in the management of severe SLE, particularly when other options are limited or unsuitable.